Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Neurocrine Biosciences (Nasdaq: NBIX) has announced its Q2 2024 financial results conference call and webcast scheduled for August 1, 2024, at 5:00 a.m. PT (8:00 a.m. ET). The press release will be issued at 4:00 a.m. PT (7:00 a.m. ET) on the same day. Domestic participants can dial 800-445-7795, while international callers can use 785-424-1699 with the conference ID 'NBIX'.
The webcast will be accessible via Neurocrine's website under the Investors section. A replay will be available an hour after the event and archived for a month. Neurocrine Biosciences is a neuroscience-focused biopharma company, offering FDA-approved treatments for various neurological and neuroendocrine disorders and has a strong pipeline of therapies in development.
- Neurocrine Biosciences is set to announce its Q2 2024 financial results, indicating transparency and regular communication with shareholders.
- The company has a diverse portfolio including FDA-approved treatments and multiple compounds in mid- to late-phase clinical development, showing strong research and development capabilities.
- None.
Conference Call and Webcast Scheduled for Thursday, August 1
The schedule for the press release and conference call / webcast is as follows:
• | Q2 2024 Press Release: | August 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET |
• | Q2 2024 Conference Call: | August 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET |
• | Domestic Dial-In Number: | 800-445-7795 |
• | International Dial-In Number: | 785-424-1699 |
• | Conference ID: | NBIX |
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2024-financial-results-302194771.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When is Neurocrine Biosciences announcing its Q2 2024 financial results?
What time is the Neurocrine Biosciences Q2 2024 conference call?
How can I access the Neurocrine Biosciences Q2 2024 webcast?
What is the conference ID for the Neurocrine Biosciences Q2 2024 conference call?
What is the dial-in number for domestic participants for Neurocrine Biosciences Q2 2024 conference call?
